Barclays PLC Raises Stock Holdings in InfuSystem Holdings, Inc. (NYSE:INFU)

Barclays PLC boosted its position in shares of InfuSystem Holdings, Inc. (NYSE:INFU) by 300.5% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 28,597 shares of the company’s stock after purchasing an additional 21,457 shares during the quarter. Barclays PLC owned about 0.13% of InfuSystem worth $192,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Geode Capital Management LLC increased its holdings in InfuSystem by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 436,508 shares of the company’s stock worth $2,925,000 after purchasing an additional 7,550 shares during the period. State Street Corp increased its holdings in InfuSystem by 1.1% during the 3rd quarter. State Street Corp now owns 267,012 shares of the company’s stock worth $1,789,000 after purchasing an additional 3,019 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of InfuSystem by 66.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock valued at $27,000 after acquiring an additional 1,626 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of InfuSystem in the 3rd quarter valued at $87,000. Finally, Oppenheimer Asset Management Inc. increased its holdings in shares of InfuSystem by 28.0% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 33,337 shares of the company’s stock valued at $223,000 after acquiring an additional 7,295 shares during the period. 71.13% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at InfuSystem

In other InfuSystem news, CEO Richard Dilorio sold 20,000 shares of InfuSystem stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $9.32, for a total transaction of $186,400.00. Following the completion of the sale, the chief executive officer now owns 436,659 shares of the company’s stock, valued at approximately $4,069,661.88. The trade was a 4.38 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 10.20% of the company’s stock.

InfuSystem Trading Up 3.1 %

Shares of NYSE:INFU opened at $8.23 on Wednesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.98 and a quick ratio of 1.59. The stock has a market cap of $174.97 million, a P/E ratio of 137.19 and a beta of 1.53. InfuSystem Holdings, Inc. has a 12-month low of $5.74 and a 12-month high of $10.03. The firm has a fifty day moving average of $8.54.

InfuSystem (NYSE:INFU) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.08 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.08. The firm had revenue of $35.32 million during the quarter, compared to analysts’ expectations of $35.50 million. InfuSystem had a return on equity of 2.78% and a net margin of 1.12%. Research analysts predict that InfuSystem Holdings, Inc. will post 0.15 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on INFU. B. Riley began coverage on InfuSystem in a report on Thursday, September 26th. They issued a “buy” rating and a $13.00 price target on the stock. StockNews.com upgraded InfuSystem from a “buy” rating to a “strong-buy” rating in a report on Friday, November 8th.

InfuSystem Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.